Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory Board

March 12, 2015

Live imaging reveals a new role for the sigma-1 (σ1) receptor in allowing microglia to leave brain injuries

March 11, 2015

Anavex to Present at Sigma-1 Receptors Symposium

March 10, 2015

Anavex Appoints Scientific Advisory Board Member with Expertise in Protein Misfolding Neurodegenerative Diseases

March 5, 2015

Anavex to Present at 27th Annual ROTH Conference on March 11th

March 3, 2015

Alzheimer’s Australia Dementia Research Foundation

March 3, 2015

ANAVEX 2-73 Could Prevent Alzheimer’s Disease in Addition to Modifying and Treating Symptoms

February 25, 2015

Anavex Reports Fiscal First Quarter 2015 Financial Results

February 18, 2015

Amarantus Announces First Alzheimer’s Biomarker Services Collaboration for LymPro Test® with Anavex Life Sciences Corp.

February 18, 2015

Anavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73 – Validation as Potential Platform Drug for Multiple Neurodegenerative Diseases

February 9, 2015

Anavex to Present at 17th Annual BIO CEO & Investor Conference on February 10th

February 4, 2015

Mitochondrial protection by the mixed muscarinic/sigma-1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Ab25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model.

January 20, 2015
1
23456789101112131415161718
…1920212223…
242526272829303132333435363738394041
42

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top